- PARP inhibitors in the therapy of ovarian cancer2019 | Faculty of Medicine in Pilsen
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors2019 | Central Library of Charles University
- PARP inhibitors in ovarian cancer FOREWORD2015 | First Faculty of Medicine
- Olaparib - the first PARP inhibitor in the treatment of malignant tumors2015 | First Faculty of Medicine
- PARP inhibitor olaparib and anti-VEGF bevacizumab - targeted treatment and efforts to improve the outcome of patients with advanced tuboovarian cancer2020 | Faculty of Medicine in Pilsen
- PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer2019 | Faculty of Medicine in Pilsen
- Niraparib as maintenance therapy after primary treatment of ovarian cancer - a case report2023 | First Faculty of Medicine
- The SC-35 Splicing Factor Interacts with RNA Pol II and A-Type Lamin Depletion Weakens This Interaction2021 | First Faculty of Medicine
- BRCA1 and BRCA2 - pathologist's starting kit2016 | Second Faculty of Medicine
- The use of niraparib in the treatment of ovarian cancer2023 | First Faculty of Medicine
- News in the targeted biological treatment of breast cancer2011 | First Faculty of Medicine
- Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma2019 | Faculty of Medicine in Pilsen
- Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents2022 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine
- Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum2016 | First Faculty of Medicine, Second Faculty of Medicine
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- Benefit of olaparib in the treatment of ovarian cancer – clinical practice2023 | Third Faculty of Medicine
- olaparib2017 | First Faculty of Medicine
- Platinum-sensitive recurrent ovarian cancer and olaparib maintenance treatment - case report2019 | First Faculty of Medicine
- Metastatic pancreatic cancer and personalized therapy: a case repor2023 | Third Faculty of Medicine
- Niraparib2021 | First Faculty of Medicine
- Personalized therapy in pancreatic cancer2023 | Third Faculty of Medicine
- Options and consequences of genetic testing in patients with high risk of breast and ovarian cancer due to BRCA1 and BRCA2 mutations2015 | Faculty of Medicine in Pilsen
- The molecular landscape of ETMR at diagnosis and relapse2019 | Second Faculty of Medicine
- Protective potential of different compounds and their combinations with MESNA against sulfur mustard-induced cytotoxicity and genotoxicity2017 | Faculty of Pharmacy in Hradec Králové
- Molecular biology testing in breast cancer2020 | First Faculty of Medicine
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Testing of mutations in BRCA1 and BECA2 genes in tumor tissues - possibilities and limitations2016 | Faculty of Medicine in Hradec Králové
- Homologous recombination DNA repair defects in PALB2-associated breast cancers2019 | First Faculty of Medicine
- AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial2023 | First Faculty of Medicine